MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma

NCT02724020 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Clear-cell Metastatic Renal Cell Carcinoma

Interventions

DRUG: Everolimus
DRUG: MLN0128
DRUG: MLN1117

Sponsor

Millennium Pharmaceuticals, Inc.